Navigation Links
Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
Date:10/22/2008

Of 51 patients in the FOLFOX arm, 23 achieved disease control, including five with partial responses (or 13 percent of evaluable patients). Nine patients in the FOLFOX arm were either not evaluable or too early to evaluate.

"These interim, proof-of-concept Phase 2 colorectal cancer study results are encouraging and continue to suggest the potential of picoplatin as a neuropathy-sparing first-line therapy for metastatic colorectal cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "We are committed to developing picoplatin as a preferred platinum therapy for patients with metastatic colorectal cancer who cannot tolerate the toxicity profile of currently marketed platinums, and we are optimistic that the additional data from this trial support that strategy. We are continuing to observe the study population in order to obtain progression-free and overall survival data, potentially supporting the future development of picoplatin."

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in CRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evalu
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced the ... Growth, Trends & Forecasts (2014-2020)" report to their ... is estimated at $0.17 billion by 2018 at a ... The near future will bring Biomedical sensors that are ... sensors can be set to trigger alerts when unpredictable ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Middle East & Africa Biomedical Sensors Market ... their offering. The Middle ... estimated at $0.84 billion by 2018 at a CAGR ... near future will bring Biomedical sensors that are adaptable ...
(Date:8/31/2015)... MARLBOROUGH, Mass. , Aug. 31, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today announced that the 30-day review period ... Drug (IND) for ocular indications with the U.S. ... the IND is now active. ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, Inc., ... of novel cancer immunotherapies, announced today that it has ... Executive Officer and William Ho , M.D., Ph.D., ... an experienced management team led by veterans of Flexus ... Ph.D., Chief Scientific Officer; Jay Powers , Ph.D., ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... 4, 2010 -- Thin layers of oxide materials and their ... the first time by researchers at the Center for Nanophase ... Laboratory, providing new insight into the complicated link between their ... ability to see in color, or in 3-D," said the ...
... Aug. 4 Forte, LLC, today ... web-based probate database and estate recovery application that ... Finder OnDemand provides access to a proprietary database ... powerful matching algorithms that accurately match deceased accounts ...
... Aug. 4 New England Biolabs is ... Genome Sciences Center has selected New England Biolabs as ... construction reagents. NEBNext DNA Sample Prep Reagent Sets contain ... for sample preparation for next generation sequencing, as well ...
Cached Biology Technology:Unprecedented look at oxide interfaces reveals unexpected structures on atomic scale 2Forte Launches Probate Finder OnDemand™ 2Forte Launches Probate Finder OnDemand™ 3Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 2Canada's Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing 3
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... and Edythe L. Broad Institute of Harvard and MIT ("the ... from the Boston-based Klarman Family Foundation to support a new ... This grant will allow the scientific community to ... health and disease, paving the way for major treatment breakthroughs. ...
... new system for delivering a drug to organ transplant patients, ... being developed by scientists at the University of Strathclyde in ... transplant operations and helps prevent the patient,s body rejecting the ... which the most serious problems are kidney and liver damage, ...
... 26, 2012   Reportlinker.com announces that a ... its catalogue: Biometrics Market ... TechNavio,s analysts forecast the ... a CAGR of 42.4 percent over the ...
Cached Biology News:Broad Institute awarded $32.5 million grant to launch new 'Cell Observatory' 2Broad Institute awarded $32.5 million grant to launch new 'Cell Observatory' 3System to deliver organ transplant drug -- without harmful side effects 2Biometrics Market in India 2010 - 2014 2
... Fragment, Exonuclease Minus, is a DNA-dependent DNA ... the 3´→5´ exonuclease activities present in intact ... is used for random primer labeling (3,4) ... Fragment, Exonuclease Minus, will leave a single-base ...
SMVT (N-14)...
...
... Dideoxycytidine is a cytidine analog that has ... activity. Immunogen: Chemical / Small ... The specificity of the ddC antiserum was determined ... ddC to moles of ddC analog at the ...
Biology Products: